Evidence map›Paper›PMID 36044833›Full record

ArticleOncology2022

Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience - A Multicenter Retrospective Study.

Mariam Jafri, Hartmut Kristeleit, Vivek Misra, Mark Baxter, Samreen Ahmed, Apurna Jegannathen, Ankit Jain, David Maskell, Urmila Barthakur, Gwenllian Edwards and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mariam JafriMedical Oncology, University Hospitals Birmingham Foundation Trust, Birmingham, UK.
Hartmut KristeleitDepartment of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Vivek MisraClinical Oncology, The Christie NHS Foundation Trust, Cancer Centre, Manchester, UK.
Mark BaxterMolecular and Clinical Medicine, Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
Samreen AhmedMedical Oncology, University Hospitals of Leicester, Leicester, UK.
Apurna JegannathenClinical Oncology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.
Ankit JainMedical Oncology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK.
David MaskellClinical Oncology, Norfolk and Norwich University Hospitals NHS Trust, Norwich, UK.
Urmila BarthakurClinical Oncology, Taunton and Somerset Foundation Trust, Taunton, UK.
Gwenllian EdwardsOncology, Velindre University NHS Trust, Cardiff, UK.
Harriet S WalterDepartment of Oncology, University Hospitals of Leicester, Leicester, UK.
Richard WalshawDivision of Cancer Sciences, The Christie NHS Foundation Trust, Cancer Centre, Manchester, UK.
Madeha KhanOncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Annabel BorleyClinical Oncology, Velindre University NHS Trust, Cardiff, UK.
Daniel ReaMedical Oncology, University Hospitals Birmingham Foundation Trust, Birmingham, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study examined real-world data from patients who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK.

methodsAnonymized data were collected retrospectively from patients with MBC who had received eribulin. The data included the hormone-receptor status, histological diagnosis, age, prior chemotherapy, response to eribulin, progression-free survival (PFS), and overall survival (OS).

resultsAmong 577 patients analyzed, the median age was 56 years, and most patients (73%) were estrogen-receptor positive. The median OS was 288 days (95% confidence interval [CI]: 261-315), and the PFS was 117 days (95% CI: 105-129). The median OS was higher among older patients (≥65 vs. <65 years: 325 days [95% CI: 264-385] vs. 285 days [95% CI: 252-317]; p = 0.028). The median OS was also higher in patients who received eribulin after fewer prior lines of chemotherapy (≤2 vs. >2 prior: 328 days [95% CI: 264-385] vs. 264 days [95% CI: 229-298]; p = 0.042). DISCUSSION/

conclusionThese retrospective data suggest that eribulin can be successfully used in older patients with MBC. Eribulin treatment was more effective in earlier-line settings, which, while predictable, supports consideration of eribulin as a second-line treatment option.

Indexed as

Breast NeoplasmsAgedFemaleFuransHumansKetonesMiddle AgedPolyether PolyketidesRetrospective StudiesTreatment OutcomeUnited KingdomeribulinFuransKetonesPolyether PolyketidesEribulinMetastatic breast cancerObservation studyOlder adultsReal-world dataSecond-line treatment

Identifiers

PMID36044833
PMCPMC9808648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.